117 related articles for article (PubMed ID: 1902546)
1. Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man.
Dobs AS; Levine MA; Margolis S
Metabolism; 1991 May; 40(5):524-8. PubMed ID: 1902546
[TBL] [Abstract][Full Text] [Related]
2. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
Saito Y; Goto Y; Nakaya N; Hata Y; Homma Y; Naito C; Hayashi H; Ito H; Yamamoto M; Takeuchi I
Atherosclerosis; 1988 Aug; 72(2-3):205-11. PubMed ID: 3145746
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.
Miettinen TA
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S19-21. PubMed ID: 1904356
[TBL] [Abstract][Full Text] [Related]
5. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
[TBL] [Abstract][Full Text] [Related]
6. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
[TBL] [Abstract][Full Text] [Related]
7. Pravastatin, a HMG-CoA reductase inhibitor, blocks the cell cycle progression but not Ca2+ influx induced by IGF-I in FRTL-5 cells.
Tada H; Takada K; Amino N; Miyai K
Biochem Biophys Res Commun; 1991 May; 177(1):17-21. PubMed ID: 1645956
[TBL] [Abstract][Full Text] [Related]
8. The effect of pravastatin on serum cholesterol levels in hypercholesterolemic diabetic rabbits.
Arbeeny CM; Bergquist KE
Biochim Biophys Acta; 1991 Apr; 1096(3):238-44. PubMed ID: 1902119
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation.
Muraca M; Baggio G; Miconi L; Vilei MT; Martini S; Gabelli C; Belluco C; Lise M; Crepaldi G
Eur J Clin Invest; 1991 Apr; 21(2):204-8. PubMed ID: 1905632
[TBL] [Abstract][Full Text] [Related]
10. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
Watanabe Y; Ito T; Shiomi M; Tsujita Y; Kuroda M; Arai M; Fukami M; Tamura A
Biochim Biophys Acta; 1988 Jun; 960(3):294-302. PubMed ID: 3132979
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.
Pan HY
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S15-8. PubMed ID: 1904355
[TBL] [Abstract][Full Text] [Related]
12. The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers.
Nakaya N; Homma Y; Tamachi H; Goto Y
Atherosclerosis; 1986 Aug; 61(2):125-8. PubMed ID: 3092836
[TBL] [Abstract][Full Text] [Related]
13. [Effect of pravastatin on hepatic cholesterol metabolism].
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
Fortschr Med; 1991 Mar; 109(8):189-94. PubMed ID: 1905265
[TBL] [Abstract][Full Text] [Related]
14. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites.
Ismail F; Corder CN; Epstein S; Barbi G; Thomas S
Clin Ther; 1990; 12(5):427-30. PubMed ID: 2125243
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
16. Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
Hirano T; Komuro F; Furukawa S; Nagano S; Takahashi T
Metabolism; 1990 Jun; 39(6):605-9. PubMed ID: 2112675
[TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering diets in patients taking pravastatin, a new HMG-CoA reductase inhibitor: compliance and adequacy.
Dobs AS; Sarma PS; Wilder L
Am J Clin Nutr; 1991 Oct; 54(4):696-700. PubMed ID: 1910254
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W
Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
[TBL] [Abstract][Full Text] [Related]
19. Escape phenomenon occurs by lowering cholesterol with a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor in patients with familial hypercholesterolemia.
Yamamoto A; Yokoyama S; Yamamura T
Atherosclerosis; 1988 Jun; 71(2-3):257-60. PubMed ID: 3135813
[TBL] [Abstract][Full Text] [Related]
20. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.
Singhvi SM; Pan HY; Morrison RA; Willard DA
Br J Clin Pharmacol; 1990 Feb; 29(2):239-43. PubMed ID: 2106337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
